Effect of Algorithm Aggressiveness on the Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System

Background: The Hypoglycemia-Hyperglycemia Minimizer (HHM) System aims to mitigate glucose excursions by preemptively modulating insulin delivery based on continuous glucose monitor (CGM) measurements. The “aggressiveness factor” is a key parameter in the HHM System algorithm, affecting how readily the system adjusts insulin infusion in response to changing CGM levels. Methods: Twenty adults with type 1 diabetes were studied in closed-loop in a clinical research center for approximately 26 hours. This analysis focused on the effect of the aggressiveness factor on the insulin dosing characteristics of the algorithm and, to a lesser extent, on the glucose control results observed. Results: As the aggressiveness factor increased from conservative to medium to aggressive: the maximum observed insulin dose delivered by the algorithm—which is designed to give doses that are corrective in nature every 5 minutes—increased (1.00 vs 1.15 vs 2.20 U, respectively); tendency to adhere to the subject’s nominal basal dose decreased (61.9% vs 56.6% vs 53.4%); and readiness to decrease insulin below basal also increased (18.4% vs 19.4% vs 25.2%). Glucose analyses by both CGM and Yellow Springs Instruments (YSI) indicated that the aggressive setting of the algorithm resulted in the least time spent at levels >180 mg/dL, and the most time spent between 70-180 mg/dL. There was no severe hyperglycemia, diabetic ketoacidosis, or severe hypoglycemia for any of the aggressiveness values investigated. Conclusions: These analyses underscore the importance of investigating the sensitivity of the HHM System to its key parameters, such as the aggressiveness factor, to guide future development decisions.

[1]  Howard C. Zisser,et al.  Clinical Evaluation of a Personalized Artificial Pancreas , 2013, Diabetes Care.

[2]  Eyal Dassau,et al.  Closed-Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a Feasibility Study , 2014, Journal of diabetes science and technology.

[3]  Eyal Dassau,et al.  Modular Artificial β-Cell System: A Prototype for Clinical Research , 2008 .

[4]  Aaron J. Kowalski,et al.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. , 2009, Diabetes technology & therapeutics.

[5]  Howard C. Zisser,et al.  Fully Integrated Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes.

[6]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[7]  F. El-Khatib,et al.  Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas , 2012, Diabetes Care.

[8]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[9]  J. Stockman,et al.  Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial , 2011 .

[10]  Eyal Dassau,et al.  Modular artificial beta-cell system: a prototype for clinical research. , 2008, Journal of diabetes science and technology.

[11]  C. Goodman,et al.  Food and Drug Administration Center for Devices and Radiological Health , 1988 .